June 26, 2025

Opus Genetics VEGA-3 Phase 3 Trial Meets Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for Presbyopia

27.2% of participants treated with phentolamine ophthalmic solution 0.75% achieved at least a 15-letter improvement in binocular DCNVA, with less than a 5-letter loss in binocular BCDVA at 12 hours postdose on Day 8, compared with 11.5% of patients on placebo (P < .001).

Ophthalmology Management

June 25, 2025

ABB Optical Group Opens Registration for 11th Annual Optometry Student Challenge

ABB Optical Group is accepting registrations for its 11th annual Optometry Student Challenge, an educational competition designed for third- and fourth-year optometry students.

Eyecare Business

June 25, 2025

RayOne EMV: Enhancing Vision

RayOne EMV’s non-diffractive design provides a versatile and effective solution for post-laser vision correction eyes – and more

The Ophthalmologist

June 25, 2025

New CLI Report Reveals Online Search Trends in Contact Lens Consumers

The report provides how-to articles, infographics, and more to help eyecare professionals adapt communication, education, and practice management strategies based on evolving digital behaviors.

Optometric Management

June 24, 2025

Vision Expo to Transition to Single Annual Event Beginning in 2026

“We’re creating space for greater innovation, stronger partnerships, & growth,” says TVC CEO Ashley Mills.

Eyecare Business

June 23, 2025

ASPECT Trial Shows Efficacy of Combined Atropine and DIMS Lenses for Pediatric Myopia

Nearly 40% of patients on combined therapy achieved zero axial elongation over 12 months.

Contact Lens Spectrum

June 22, 2025

TFOS Completes DEWS III

Updates on recommendations & conclusions of TFOS DEWS II.

Contact Lens Spectrum

June 20, 2025

Updates in Uveitis Guidance

New review provides an overview of classification, diagnostics, and treatments

Ophthalmology Management

June 20, 2025

Foundation Fighting Blindness Submits Testimony to Congress for NEI Funding

The testimony urged US Senate subcommittee to deliver strong, sustained funding for the NEI and maintain the NEI’s status as an independent NIH institute in the FY2026 appropriations cycle.

Optometric Management